Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results

Pivotal Phase III Trial Primary Endpoints Achieved for SCOLR's 12-Hour


BOTHELL, Wash., Nov. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) today reported financial results for the three and nine months ended September 30, 2008. The Company will host a live conference call today, November 7, 2008, at 11:30 a.m. (Eastern Standard Time).

Daniel O. Wilds, SCOLR Pharma's President and CEO, said, "We had a very productive third quarter making significant progress advancing our lead product candidates and securing additional non-dilutive operating capital while maintaining financial discipline. Most importantly, yesterday we reported favorable top-line results from our pivotal Phase III trial to evaluate the safety and efficacy of our 12 hour CDT(R) 600 mg extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The trial incorporated FDA special protocol assessment design elements, met both co-primary endpoints (p<0.0001), and had no significant adverse events. This successful trial is an extremely important milestone for the Company. We expect that the successful results of this study will focus the attention of potential partners and facilitate an alliance for our lead product candidate."

Also during the quarter, SCOLR submitted an Abbreviated New Drug Application (ANDA) for a 120 milligram 12-hour pseudoephedrine tablet based on our patented Controlled Delivery Technology (CDT(R)) platform. Subsequently, we reported that the U.S. FDA had accepted our submission for review. This is the first product approval application filed by SCOLR Pharma, and, if approved, would further demonstrate the novel advantages of our proprietary drug delivery technology.

The Company also completed its previously announced lease termination and buyout transaction under which we received $4.1 million and successfully relocated its corporate headquarters to a more cost effective and better equipped facility."

Mr. Wilds concluded, "We are very encouraged by our achievement of important business and clinical milestones during the past quarter. By continuing to focus on partnering our lead product candidates, limiting additional drug development initiatives to those already partnered and in active collaborations, we expect that the net proceeds from the lease buyout and our current financial resources together with continuing expense management should be sufficient to fund our operations through 2009."

Total revenues, which consist of royalty revenue from our collaboration agreements, increased 14%, or $28,834 to $236,308 for the three months ended September 30, 2008, compared to $207,474 for the same period in 2007. This increase is primarily due to higher royalty income from our relationship with Perrigo.

Total revenues decreased 55% or $968,013 to $781,435 for the nine months ended September 30, 2008, compared to $1.7 million for the same period in 2007. The higher total revenues for 2007 were primarily due to approximately $621,222 of research and development fees and licensing revenues from an agreement terminated in the first quarter of 2007.

Net income for the three months ended September 30, 2008, was $890,370 compared to a net loss of ($3.1) million for the same period in 2007. Net loss for the nine months ended September 30, 2008, decreased 55%, or $3.9 million to $3.2 million, compared with a net loss of $7.1 million for the same period in 2007. The decrease in the net loss was primarily due to the $4.0 million net gain from the termination of the lease on our corporate facility.

In May 2008, we entered into an agreement to terminate the lease of our corporate facility for $4.1 million. Under the terms of the agreement, $1.0 million was paid upon execution of the agreement and the remaining $3.1 million was paid in September when we vacated our premises. We recognized in operating expense, the gain of $4.1 million and $116,867 of expense related to the new lease and our relocation to the new facility in September 2008.

Total operating expenses for the third quarter of 2008 were $(611,506), which included $4.0 million net lease termination gain, compared to $3.5 million in the same period in 2007. Total operating expenses decreased 55% to $4.2 million for the nine months ended September 30, 2008, from $9.4 million for the same period in 2007. The decreases in operating expenses were primarily due to the net gain of $4.0 million from the lease termination and surrender agreement associated with our corporate facility.

SCOLR had approximately $8.9 million in cash and cash equivalents, and $564,000 in restricted cash as of September 30, 2008. The Company is investing its cash and cash equivalents in government-backed securities.

Conference Call

As previously announced, SCOLR Pharma will host a conference call on November 7, 2008, at 11:30 a.m. (Eastern Standard Time). Shareholders and other interested parties may participate in the conference call by dialing +1- 888-713-4215 (domestic) or +1 617-213-4867 (international) and entering access code 67625263, a few minutes before 11:30 a.m. EST on November 7, 2008. The call will also be broadcast live on the Internet at, or

A replay of the conference call will be accessible two hours after its completion through November 21, 2008, by dialing +1-888-286-8010 (domestic) or +1 617-801-6888 (international) and entering access code 60696221. The call will also be archived for 90 days at, or

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning our ability to fund our operations through 2009, the success of our products in the marketplace and in clinical trials and the availability of potential partners. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including unanticipated costs and expenses associated with our product development and clinical activities, reductions in our royalty revenues, our ability to successfully develop new formulations and complete research and development, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.

Financial Information

SCOLR Pharma, Inc.


September 30, December 31,

2008 2007



Current Assets

Cash and cash equivalents $8,908,986 $11,825,371

Accounts receivable 244,214 225,900

Interest and other receivables - 16

Prepaid expenses and other assets 323,407 432,213

Total current assets 9,476,607 12,474,500

Property and Equipment - net of

accumulated depreciation of

$1,213,775 and $964,738, respectively 502,510 748,931

Intangible assets - net of

accumulated amortization of $443,435

and $385,452, respectively 522,403 464,023

Restricted cash 564,000 -

$11,065,520 $13,687,454


Current Liabilities

Accounts payable $324,890 $757,420

Accrued expenses 738,330 586,849

Current portion of term loan 85,831 80,047

Total current liabilities 1,149,051 1,424,316

Long-term portion of term loan 46,004 111,119

Total liabilities 1,195,055 1,535,435

Commitments and Contingencies

Stockholders' Equity

Preferred stock, authorized 5,000,000

shares, $.01 par value, none

issued or outstanding - -

Common stock, authorized 100,000,000

shares, $.001 par value, 41,130,270

and 40,991,385 issued and outstanding

as of September 30, 2008, and

December 31, 2007, respectively 41,130 40,991

Additional paid-in capital 70,879,940 69,945,666

Accumulated deficit (61,050,605) (57,834,638)

Total stockholders' equity 9,870,465 12,152,019

$11,065,520 $13,687,454

SCOLR Pharma, Inc.



Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007


Licensing fees $- $- $- $173,077

Royalty income 236,308 207,474 781,435 955,149

Research and

development income - - - 621,222

Total revenues 236,308 207,474 781,435 1,749,448

Operating expenses

Marketing and selling 116,840 198,520 545,579 673,776

Research and

development 2,307,103 2,236,852 4,387,636 5,410,226

General and

administrative 947,684 1,017,177 3,242,614 3,305,918

3,371,627 3,452,549 8,175,829 9,389,920

Facility lease


Gain from lease

buyout (4,100,000) - (4,100,000) -

Expenses related

to relocation

and lease Buyout 116,867 - 116,867 -

Total facility

lease buyout (3,983,133) - (3,983,133) -

Total operating

expenses (611,506) 3,452,549 4,192,696 9,389,920

Income or (loss)

from operations 847,814 (3,245,075) (3,411,261) (7,640,472)

Other income (expense)

Interest income 45,858 160,080 205,530 550,402

Interest expense (3,393) (5,191) (11,565) (10,967)

Other 91 - 1,329 2,941

Total other

income (expense) 42,556 154,889 195,294 542,376

Net income or (loss) $890,370 $(3,090,186) $(3,215,967) $(7,098,096)

Net income (loss)

per share, basic

and diluted $ .02 $(0.08) $(0.08) $(0.19)

Shares used in

computing basic

net income (loss)

per share 41,043,770 38,153,316 41,037,128 38,123,071

Shares used in

computing diluted

net income (loss)

per share 41,561,623 38,153,316 41,037,128 38,123,071

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
3. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
4. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
(Date:11/30/2015)... VIEW, Calif. , Nov. 30, 2015 ... been the norm in U.S. medical imaging ... The increasingly popular accountable care payer-provider contracts ... models and, in their wake, alter provider-vendor ... quality-based payments will push forward new purchasing ...
(Date:11/30/2015)... and SAN DIEGO , ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that ... for filing the New Drug Application (NDA) for an ... release formulation will offer patients a chronic weight management ... ® ) is currently approved as an adjunct to ...
(Date:11/30/2015)... and ST. LOUIS , Nov. 30, ... ESRX ) today announced an early renewal of ... began in 1999, will now extend through at least ... After evaluating pharmacy benefit manager capabilities during a ... Scripts continues to offer the best health plan integration ...
Breaking Medicine Technology:
(Date:11/30/2015)... Los Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... music star Jessie James Decker made a brave but slightly unusual choice to show ... quickly returning to her pre-pregnancy form may have been pre-mature. Saying that she didn’t ...
(Date:11/30/2015)... ... November 30, 2015 , ... A record crowd gathered at the Pennsylvania Biotech ... the Baruch S. Blumberg Institute. , The institute, which is the research arm of ... biotechnology leaders for the conference, which focused on ways companies can work to reduce ...
(Date:11/30/2015)... Scotch Plains, NJ (PRWEB) , ... November 30, 2015 , ... ... patients in a comfortable and convenient setting. , When you have dental problems, you ... knows the field and can effectively diagnose and treat your needs, a friendly dentist ...
(Date:11/30/2015)... Scotch Plains, NJ (PRWEB) , ... November 30, 2015 , ... ... third generation dentist. His grandfather graduated from Tufts School of Dental Medicine in ... celebrates 80 years for the Isola family being in dentistry as well as their ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation ... cancer education and prevention—is joining forces with the award-winning creator and writer of ... on December 7, 2015 at the Union League of Philadelphia. , The ...
Breaking Medicine News(10 mins):